REFERENCES
1. Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381:626-36.
2. Zhang L, Shen D, Feng J, Tang L. Targeted therapy in BRAF‑mutant melanoma: advances and challenges (Review). Int J Oncol. 2026;69:1-17.
3. Tangella LP, Clark ME, Gray ES. Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - a mini review. Biochim Biophys Acta Gen Subj. 2021;1865:129736.
4. He X, Deng H, Liu W, Hu L, Tan X. Advances in understanding drug resistance mechanisms and innovative clinical treatments for melanoma. Curr Treat Options Oncol. 2024;25:1615-33.
5. Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141:69-80.
6. Hammerlindl H, Schaider H. Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance. J Cell Commun Signal. 2018;12:133-41.
7. Ravindran Menon D, Hammerlindl H, Gimenez G, et al. H3K4me3 remodeling induced acquired resistance through O-GlcNAc transferase. Drug Resist Updat. 2023;71:100993.
8. Pu Y, Li L, Peng H, et al. Drug-tolerant persister cells in cancer: the cutting edges and future directions. Nat Rev Clin Oncol. 2023;20:799-813.
9. Mikubo M, Inoue Y, Liu G, Tsao MS. Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy. J Thorac Oncol. 2021;16:1798-809.
10. Szlasa W, Zendran I, Zalesińska A, Tarek M, Kulbacka J. Lipid composition of the cancer cell membrane. J Bioenerg Biomembr. 2020;52:321-42.
11. Peetla C, Bhave R, Vijayaraghavalu S, Stine A, Kooijman E, Labhasetwar V. Drug resistance in breast cancer cells: biophysical characterization of and doxorubicin interactions with membrane lipids. Mol Pharm. 2010;7:2334-48.
12. Peetla C, Vijayaraghavalu S, Labhasetwar V. Biophysics of cell membrane lipids in cancer drug resistance: implications for drug transport and drug delivery with nanoparticles. Adv Drug Deliv Rev. 2013;65:1686-98.
13. Piatrikova V, Kocianova E, Skvarkova L, Golias T. Fuelling resistance: lipid metabolic rewiring in cancer response to chemotherapy and radiotherapy. Biomed Pharmacother. 2025;193:118715.
14. Zhang J, Li Q, Wu Y, et al. Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer. Cell Commun Signal. 2019;17:15.
15. Raghavan V, Vijayaraghavalu S, Peetla C, Yamada M, Morisada M, Labhasetwar V. Sustained epigenetic drug delivery depletes cholesterol-sphingomyelin rafts from resistant breast cancer cells, influencing biophysical characteristics of membrane lipids. Langmuir. 2015;31:11564-73.
16. Benfield AH, Vernen F, Young RSE, et al. Cyclic tachyplesin I kills proliferative, non-proliferative and drug-resistant melanoma cells without inducing resistance. Pharmacol Res. 2024;207:107298.
17. Benfield AH, Vernen F, Young RSE et al. Membrane-active peptides escape drug-resistance in cancer. bioRxiv. 2022.
18. Matyash V, Liebisch G, Kurzchalia TV, Shevchenko A, Schwudke D. Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. J Lipid Res. 2008;49:1137-46.
19. Lorent JH, Levental KR, Ganesan L, et al. Plasma membranes are asymmetric in lipid unsaturation, packing and protein shape. Nat Chem Biol. 2020;16:644-52.
20. Young RSE, Bowman AP, Williams ED, et al. Apocryphal FADS2 activity promotes fatty acid diversification in cancer. Cell Rep. 2021;34:108738.
21. Liebisch G, Binder M, Schifferer R, Langmann T, Schulz B, Schmitz G. High throughput quantification of cholesterol and cholesteryl ester by electrospray ionization tandem mass spectrometry (ESI-MS/MS). Biochim Biophys Acta. 2006;1761:121-8.
22. Colom A, Derivery E, Soleimanpour S, et al. A fluorescent membrane tension probe. Nat Chem. 2018;10:1118-25.
23. Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676-82.
24. Burri O, Sobolewski P, Fehlmann T. BIOP/qupath-extension-cellpose. Improved label image reading and code linting (v0.9.6). 2024. Available from: https://github.com/BIOP/qupath-extension-cellpose. [Last accessed on 10 Sep 2026].
25. Pachitariu M, Rariden M, Stringer C. Cellpose-SAM: superhuman generalization for cellular segmentation. bioRxiv. 2025.
26. Germain N, Dhayer M, Boileau M, Fovez Q, Kluza J, Marchetti P. Lipid metabolism and resistance to anticancer treatment. Biology. 2020;9:474.
27. Wang R, Yan Q, Liu X, Wu J. Unraveling lipid metabolism reprogramming for overcoming drug resistance in melanoma. Biochem Pharmacol. 2024;223:116122.
28. Canaparo R, Foglietta F, Pepa CD, Serpe L. Spotlight on membrane fluidity of normal and cancer cells: implications for cancer diagnosis and treatment. Eur J Pharmacol. 2025;1006:178152.
29. Baccouch R, Shi Y, Vernay E, et al. The impact of lipid polyunsaturation on the physical and mechanical properties of lipid membranes. Biochim Biophys Acta Biomembr. 2023;1865:184084.
30. Subczynski WK, Pasenkiewicz-Gierula M, Widomska J, Mainali L, Raguz M. High cholesterol/low cholesterol: effects in biological membranes: a review. Cell Biochem Biophys. 2017;75:369-85.
31. Chakraborty S, Doktorova M, Molugu TR, et al. How cholesterol stiffens unsaturated lipid membranes. Proc Natl Acad Sci U S A. 2020;117:21896-905.
32. Kay JG, Koivusalo M, Ma X, Wohland T, Grinstein S. Phosphatidylserine dynamics in cellular membranes. Mol Biol Cell. 2012;23:2198-212.
33. Leventis PA, Grinstein S. The distribution and function of phosphatidylserine in cellular membranes. Annu Rev Biophys. 2010;39:407-27.
34. Sharma B, Kanwar SS. Phosphatidylserine: a cancer cell targeting biomarker. Semin Cancer Biol. 2018;52:17-25.
35. Preetam S, Pandey A, Mishra R, et al. Phosphatidylserine: paving the way for a new era in cancer therapies. Mater Adv. 2024;5:8384-403.
36. Hu S, Chen J, Hu Y, et al. The intensity of cell surface charge defines the malignancy of cancer cells. Chem Eng J. 2025;519:164948.
37. Zalba S, Ten Hagen TL. Cell membrane modulation as adjuvant in cancer therapy. Cancer Treat Rev. 2017;52:48-57.
38. Shimolina L, Gulin A, Khlynova A, et al. Effects of paclitaxel on plasma membrane microviscosity and lipid composition in cancer cells. Int J Mol Sci. 2023;24:12186.
39. Harris FM, Best KB, Bell JD. Use of laurdan fluorescence intensity and polarization to distinguish between changes in membrane fluidity and phospholipid order. Biochim Biophys Acta. 2002;1565:123-8.
40. Amaro M, Reina F, Hof M, Eggeling C, Sezgin E. Laurdan and Di-4-ANEPPDHQ probe different properties of the membrane. J Phys D Appl Phys. 2017;50:134004.
41. Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45:D353-61.
42. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27-30.
43. Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2016;44:D457-62.
44. Wei J, Hu M, Huang K, Lin S, Du H. Roles of proteoglycans and glycosaminoglycans in cancer development and progression. Int J Mol Sci. 2020;21:5983.
45. Ribeiro AR, Marques C, Reis CA, Magalhães A. Glycosaminoglycans in gastrointestinal cancer: from biosynthesis to tumor signatures. Am J Physiol Cell Physiol. 2025;329:C1604-23.
46. Quinville BM, Deschenes NM, Ryckman AE, Walia JS. A comprehensive review: sphingolipid metabolism and implications of disruption in sphingolipid homeostasis. Int J Mol Sci. 2021;22:5793.
47. Kuo A, Hla T. Regulation of cellular and systemic sphingolipid homeostasis. Nat Rev Mol Cell Biol. 2024;25:802-21.
48. Lee H, Park S, Lee J, et al. Lipid metabolism in cancer stem cells: reprogramming, mechanisms, crosstalk, and therapeutic approaches. Cell Oncol. 2025;48:1181-201.
49. Lin J, Lai Y, Lu F, Wang W. Targeting ACSLs to modulate ferroptosis and cancer immunity. Trends Endocrinol Metab. 2025;36:677-90.
50. Cheng Z, Montgomery MK. Physiological roles of phosphoinositides and inositol phosphates: implications for metabolic dysfunction-associated steatotic liver disease. Clin Sci. 2025;139:1095-144.
51. Collins DM, Janardan V, Barneda D, et al. CDS2 expression regulates de novo phosphatidic acid synthesis. Biochem J. 2024;481:1449-73.
52. Llorente A, Arora GK, Murad R, Emerling BM. Phosphoinositide kinases in cancer: from molecular mechanisms to therapeutic opportunities. Nat Rev Cancer. 2025;25:463-87.
53. Liu R, Chen Y, Liu G, et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;11:797.
54. Govindarajan B, Sbrissa D, Pressprich M, et al. Adaptor proteins mediate CXCR4 and PI4KA crosstalk in prostate cancer cells and the significance of PI4KA in bone tumor growth. Sci Rep. 2023;13:20634.
55. Pencheva N, Tran H, Buss C, et al. Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis. Cell. 2012;151:1068-82.
56. Zhou Y, Luo G. Apolipoproteins, as the carrier proteins for lipids, are involved in the development of breast cancer. Clin Transl Oncol. 2020;22:1952-62.
57. Yang LG, March ZM, Stephenson RA, Narayan PS. Apolipoprotein E in lipid metabolism and neurodegenerative disease. Trends Endocrinol Metab. 2023;34:430-45.
58. Go GW, Mani A. Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis. Yale J Biol Med. 2012;85:19-28.
59. Sun T, Xiao X. Targeting ACAT1 in cancer: from threat to treatment. Front Oncol. 2024;14:1395192.
60. Ravindran Menon D, Das S, Krepler C, et al. A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene. 2015;34:4448-59.
61. Cabanos HF, Hata AN. Emerging insights into targeted therapy-tolerant persister cells in cancer. Cancers. 2021;13:2666.
62. De Conti G, Dias MH, Bernards R. Fighting drug resistance through the targeting of drug-tolerant persister cells. Cancers. 2021;13:1118.
63. He J, Qiu Z, Fan J, Xie X, Sheng Q, Sui X. Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies. Signal Transduct Target Ther. 2024;9:209.
64. Lamb HO, Benfield AH, Henriques ST. Peptides as innovative strategies to combat drug resistance in cancer therapy. Drug Discov Today. 2024;29:104206.
65. Zakany F, Mándity IM, Varga Z, Panyi G, Nagy P, Kovacs T. Effect of the lipid landscape on the efficacy of cell-penetrating peptides. Cells. 2023;12:1700.
66. Alves AC, Ribeiro D, Nunes C, Reis S. Biophysics in cancer: the relevance of drug-membrane interaction studies. Biochim Biophys Acta. 2016;1858:2231-44.
67. Zhang Y, Zeng W, Jia F, et al. Cisplatin‐induced alteration on membrane composition of A549 cells revealed by ToF‐SIMS. Surf Interface Anal. 2020;52:256-63.
68. Todor IN, Lukyanova NY, Chekhun VF. The lipid content of cisplatin- and doxorubicin-resistant MCF-7 human breast cancer cells. Exp Oncol. 2012;34:97-100.
69. Shimolina L, Gulin A, Ignatova N, et al. The role of plasma membrane viscosity in the response and resistance of cancer cells to oxaliplatin. Cancers. 2021;13:6165.
70. Morgenstern Y, Lee J, Na Y, et al. Acute myeloid leukemia drug-tolerant persister cells survive chemotherapy by transiently increasing plasma membrane rigidity, that also increases their sensitivity to immune cell killing. Haematologica. 2025;110:893-903.
71. Chang W, Fa H, Xiao D, Wang J. Targeting phosphatidylserine for cancer therapy: prospects and challenges. Theranostics. 2020;10:9214-29.
72. Kim OH, Kang GH, Hur J, et al. Externalized phosphatidylinositides on apoptotic cells are eat-me signals recognized by CD14. Cell Death Differ. 2022;29:1423-32.
74. Shen S, Faouzi S, Souquere S, et al. Melanoma persister cells are tolerant to BRAF/MEK inhibitors via ACOX1-mediated fatty acid oxidation. Cell Rep. 2020;33:108421.
75. Redondo-Muñoz M, Caballe-Mestres A, Reisz JA, et al. Androgen receptor and fatty acid oxidation cooperate in ferroptosis evasion in BRAFi resistant melanoma. Cell Death Dis. 2026;17:338.
76. Xiao Q, Xia M, Tang W, Zhao H, Chen Y, Zhong J. The lipid metabolism remodeling: a hurdle in breast cancer therapy. Cancer Lett. 2024;582:216512.
77. Stoykova GE, Schlaepfer IR. Lipid metabolism and endocrine resistance in prostate cancer, and new opportunities for therapy. Int J Mol Sci. 2019;20:2626.
78. Bacci M, Lorito N, Smiriglia A, Morandi A. Fat and furious: lipid metabolism in antitumoral therapy response and resistance. Trends Cancer. 2021;7:198-213.
79. Kim J, Hwang YH, Nam GH, Kim IS. Breaking barriers: engineering extracellular vesicles for enhanced endosomal escape and therapeutic delivery. J Control Release. 2026;389:114462.
80. Broadfield LA, Pane AA, Talebi A, Swinnen JV, Fendt SM. Lipid metabolism in cancer: new perspectives and emerging mechanisms. Dev Cell. 2021;56:1363-93.
81. Delmas D, Mialhe A, Cotte AK, et al. Lipid metabolism in cancer: exploring phospholipids as potential biomarkers. Biomed Pharmacother. 2025;187:118095.
